InxMed
Business Services · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Tower 2 Huamao Office Building No. 79 Ji...Phone Number
+86 1085887500Website
www.inxmed.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About InxMed
InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and being a China based biotech company with global impact. We have built translational medicine and clinical development team across Shanghai, Beijing, Nanjing, United States, Canada and Australia. We have built a highly differentiated pipeline and established partnership with various multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim.Explore more
InxMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InxMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on InxMed recently announced quarterly report
Funding: Get notified immidiatlly once InxMed has new funding data
Congratulate Masked Content for being promoted to Masked Content at InxMed
Competitive Alert! Recent activity has been detected by your competitor Masked Content
InxMed, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if InxMed is spiking on competitors!
Check if InxMed has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when InxMed launches new products
Click to see if InxMed had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at InxMed
Find 3 more new buyers
Company Profile Activity
Activity Insights
InxMed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
InxMed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about InxMed.
InxMed financials insights
Gather financial insights about InxMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$19M
2022
Series B
$65M
InxMed Tech Stack
A closer look at the technologies used by InxMed
Most Recent Scoops
Hiring Plans
InxMed is hiring in Medical & Health for the first time in 12 months.
Hiring Plans
Hiring Plans
InxMed is hiring in Medical & Health for the first time in 12 months. Areas of expertise include: Medical Monitoring, Clinical Trial Protocols, Clinical Study Reports, Drug Development, Clinical Medicine, Laboratory Safety, and Investigator's Brochure.
Hiring Plans
Event
Project
Events, Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Project
Product Development, Intellectual Property, Legal Affairs
Product Launch
InxMed News & Media
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthrough Therapy designation (BTD) for the first-line (1L) treatment of non-small cell lung cancer (NSCLC) with KRAS G12C mutation in combination with garsorasib, a specific inhibitor of the KRAS G12C mutatiInxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
NANJING, China, Nov. 8, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to enhance efficacy and improve safety of ADCs, and IN30758, a First-in-class ADC for treatment of multiple solid tumorInxMed Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
Ifebemtinib in combination with garsorasib in NSCLC showed ORR of 90.3% and DCR of 96.8% Ifebemtinib is a highly selective, orally administered, focal adhesion kinase inhibitor with significant synergies with a broad spectrum of therapeutic modalities NANJING, China, May 30, 2024...InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit®...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding InxMed
Sign Up For FreeTo access detailed company insights
InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical... Read More
